Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
05/17/2017 05/18/2017 05/21/2017 05/22/2017 05/23/2017 Date
11210(c) 10730(c) 10740(c) 10700(c) 10340 Last
476 443 894 564 298 319 294 531 1 001 081 Volume
-3.86% -4.28% +0.09% -0.37% -3.36% Change
More quotes
Financials ($)
Sales 2017 23 489 M
EBIT 2017 7 190 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 4,03%
Sales 2018 23 103 M
EBIT 2018 7 021 M
Net income 2018 4 202 M
Debt 2018 21 087 M
Yield 2018 4,09%
P/E ratio 2017 7,59
P/E ratio 2018 7,35
EV / Sales2017 2,39x
EV / Sales2018 2,23x
Capitalization 30 329 M
More Financials
Company
Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services.It operates through the following two segments: Generic and Specialty Medicine.The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including... 
More about the company
Surperformance© ratings of Teva Pharmaceutical Indust
Trading Rating : Investor Rating :
More Ratings
Latest news on TEVA PHARMACEUTICAL INDUST
05/18 TEVA PHARMACEUTICAL INDUSTRIES : search committee recommends foreign CEO - repor..
05/17 TEVA PHARMACEUTICAL INDUSTRIES : to lay off 500 in Hungary - report
05/17 TEVA PHARMACEUTICAL INDUSTRIES : Showcases Asthma Research at the 2017 American ..
05/17 TEVA PHARMACEUTICAL INDUSTRIES : to Present Data for Deutetrabenazine in Tardive..
05/16 TEVA 2017 : Acquisitions out, cost-cutting in
05/15 TEVA PHARMACEUTICAL INDUSTRIES : teams with Japan's Otsuka on migraine drug
05/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Generic Glumetza® in the Un..
05/15 TEVA PHARMACEUTICAL INDUSTRIES : Otsuka and Teva Sign Licensing Agreement for Ja..
05/12 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Today's Research Reports on Stocks to Wat..
05/12 TEVA PHARMACEUTICAL INDUSTRIES : steadies the ship with firm Q1 results
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
More sector news : Pharmaceuticals - NEC
Latest Tweets
05/22Kayne Anderson Rudnick Investment Management LLC Raises Stake in Teva Pharmac.. 
05/22Teva Pharmaceutical Industries Ltd $TEVA Shares Bought by CIBC World Markets .. 
05/22NEXT Financial Group Inc Has $133,000 Position in Teva Pharmaceutical Industr.. 
05/22Teva Pharmaceutical Industries Ltd $TEVA Upgraded at Vetr Inc.
1
05/20Marble Harbor Investment Counsel LLC Sells 1,250 Shares of Teva Pharmaceutica.. 
More tweets
Qtime:29
News from SeekingAlpha
05/22 My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
05/22 TEVA : What's Going On?
05/21 MAY BUYS : The 16 Stocks Added To My Fund
05/21 Tracking John Paulson's Paulson & Company Portfolio - Q1 2017 Update
05/18 Valeant's Revenue Growth Is At Risk
Advertisement
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 37,5 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-22.34%30 329
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results